All articles

Modafinil: mechanism, indications and comparison with other wake-promoting agents

Modafinil: mechanism, indications and comparison with other wake-promoting agents

in pictures and a few words

What it is and why it matters

Modafinil is a prescription medicine. It helps people stay awake during the day when strong sleepiness is caused by an illness.

  • It is prescribed to adults
  • It does not replace sleep
  • Whether to take it and at what dose is decided by a doctor

When you can’t fight sleep by day

The main illness it is prescribed for is narcolepsy: a sleep disorder in which you feel a very strong urge to sleep during the day.

  • Less sleepiness during the day; a person stays alert longer
  • It works while the medicine is being taken
  • It also helped with strong sleepiness without a clear cause; this is how it is used in Japan

Pauses in breathing during sleep

During sleep the airways can close. These people are helped by a machine that delivers air under pressure at night.

  • If you are still sleepy during the day on the machine, modafinil reduces that sleepiness
  • It does not treat the breathing during sleep itself — the machine is still used
  • For this it is prescribed in the US, Japan, Canada and Australia, but not in the European Union
Night machine is a mustDaytime sleepiness remainsDoctor decides on modafinil

Working at night

For people who work shifts and struggle with sleep on the night shift, it is prescribed in the US, Canada and Australia.

  • It is taken about an hour before the shift starts
  • Sleepiness at night decreases but does not go away completely
  • Alertness at night may not fully return

If you are healthy

Modafinil is not officially prescribed anywhere to improve memory and attention in healthy people.

  • In well-rested people the effect on thinking is small
  • With lack of sleep it worked roughly like caffeine
  • In one study people on it overestimated their own results

How to take it

Usually once in the morning; for night work, about an hour before the shift. The dose is set by a doctor.

  • Taking it shortly before bed can make it hard to fall asleep
  • For older people and in severe liver disease the doctor may lower the dose
  • The medicine does not replace sleep

Birth control

Modafinil can weaken hormonal birth control: pills, rings, patches, implants.

  • Another or an extra method of protection is needed for the whole time you take it
  • And after stopping: one month under US rules, up to two months in Europe
  • The method of protection is chosen together with a doctor
Started modafinilHormones work weakerExtra protection needed

Important. Discuss your method of pregnancy protection with a doctor before you start taking it.

Pregnancy and breastfeeding

In Europe modafinil is suspected of possibly causing birth defects in the baby. That is why it is not used there during pregnancy.

  • In Europe it is not used during breastfeeding either
  • In the US during pregnancy — only if the benefit justifies the risk to the baby
  • The decision is made only together with a doctor

Who should see a doctor first

Modafinil is prescribed only by a doctor. It is especially important to tell them about anything on this list.

  • High blood pressure, heart rhythm problems or other heart conditions
  • Anxiety, depression, other mental health conditions or past addiction
  • Regular medicines: birth control, ciclosporin, warfarin, antidepressants
Rash or swellingStop taking itSee a doctor right away

Important. A rash, swelling of the face or lips, sudden mood changes or thoughts of suicide — stop taking it and see a doctor right away.

In one sentence

Modafinil helps people stay awake during the day in sleep disorders. It is taken only as prescribed by a doctor, and women need reliable protection against pregnancy while taking it and afterwards.

Frequently asked questions

Below are the indications in adults according to regulators' labels. In the US: excessive sleepiness in narcolepsy, obstructive sleep apnoea (only to treat the sleepiness, not the obstruction itself) and shift work disorder; in Canada and Australia, the same three with caveats. In the EU since 2011, and in the UK and Switzerland: only narcolepsy with or without cataplexy. For OSA, shift work and idiopathic hypersomnia, the CHMP concluded that the data on effectiveness were not sufficient to outweigh the risks — serious, life-threatening skin reactions (a risk that appears higher in children), and psychiatric and cardiovascular reactions. In Japan: narcolepsy, idiopathic hypersomnia and sleep apnoea in people receiving treatment for the obstruction, such as CPAP (continuous positive airway pressure). According to the manufacturer's data for 2018, modafinil is approved for narcolepsy in 36 countries and regions. It is not approved for children in either the US or the EU.

In narcolepsy in adults, according to the 2021 AASM systematic review, modafinil versus placebo lowered the Epworth Sleepiness Scale (ESS) score by 2.8 and lengthened the time to falling asleep in the Maintenance of Wakefulness Test (MWT) by 4.1 minutes; the AASM gives it a strong recommendation compared with no treatment. In two pooled 40-week open-label extensions (478 patients), the mean ESS fell from 16.5 to 12.4 by week 2 and stayed at that level. In sleepiness that remains in sleep apnoea on CPAP, in a 12-week RCT (327 people) ESS fell by 4.5 points versus 1.8 on placebo, and in shift work disorder improvement on the clinician's global assessment was seen in 74% versus 36%. The effect lasts while the drug is being taken.

Improving cognitive function in healthy people is not a registered indication for modafinil in any country, and the FDA label stresses that the drug is not a replacement for sleep. In well-rested adults, the overall effect in meta-analyses is small — a standardised mean difference of 0.10 (19 single-dose studies) and 0.12 (14 studies); of individual functions, only working memory updating was significant. Under sleep deprivation, in small laboratory RCTs, modafinil acted comparably to caffeine; in one RCT in 32 military pilots, at 8 hours it outperformed a single dose of caffeine on a vigilance test and subjective sleepiness — owing to duration rather than strength of action. In one study it led people to overestimate their own performance.

It may: modafinil induces the CYP3A4/5 enzymes, and according to the labels hormonal contraceptives may work less well as a result. Under the FDA label (US), the effectiveness of steroidal contraception may be reduced during use and for 1 month after stopping, the warning also covers depot injections and implants, and an alternative or additional method is recommended. Under the EU and UK labels (SmPC), contraception is put in place before treatment starts, and an alternative or additional method is needed throughout treatment and for up to 2 months after stopping. The MHRA (UK), citing FSRH guidance, considers the copper intrauterine device (IUD), the levonorgestrel-releasing IUD and progestogen depot injections suitable. This differs from the FDA label, which includes depot injections and implants (and the patient Medication Guide also hormonal IUDs). The 2022 FSRH guidance, for a drug that is both a teratogen and an enzyme inducer, advises combining a copper or levonorgestrel IUD or a depot injection with condoms (modafinil is not named in it; the EU SmPC suspects it of teratogenicity). The method is chosen together with a doctor.

Under the EU and UK labels (SmPC), no: based on epidemiological studies and spontaneous reports, modafinil is suspected of causing congenital malformations, and it is not used during breastfeeding. The FDA label (US) keeps the older wording: in pregnancy, only if the benefit justifies the risk to the fetus; whether modafinil passes into breast milk is unknown, and caution is needed. In the final US pregnancy registry, major malformations were recorded in 13.1% of prospective live births versus 3% in the general population, but without an internal control group; data from the national registers of Denmark, Sweden and Norway and from the French SNDS database are conflicting.

In the US, modafinil is a Schedule IV controlled substance. According to the FDA label, in an inpatient abuse-potential study it produced psychoactive and euphoric effects consistent with methylphenidate, so patients are monitored for dose escalation and drug-seeking; no withdrawal symptoms were reported during 14 days after 9 weeks of use, but in narcolepsy sleepiness returned. According to the European label (SmPC), a potential for dependence has been shown in studies, and with long-term use dependence cannot be entirely excluded. In two positron emission tomography (PET) studies in healthy volunteers, modafinil at doses of 200–400 mg occupied about 39–57% of dopamine transporters, and the authors call for vigilance; the authors of one of the studies judged the occupancy to be close to that of methylphenidate, and the abuse potential, from the standpoint of dopamine transmission, as possibly comparable to it.

Share
Follow on TelegramGet new articles, research updates and practical health tips
Читать на русскомЧитати українською

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions. Full disclaimer

Ready to Take Action?

A consultation starts where the article ends: your history, your labs, a plan for your case.

Book consultationAsk a question